Sperm-Associated Antigen 9 is a Promising marker for Early Diagnosis of Endometrial Cancer

Başer, Eralp; Toğrul, Cihan; Özgü, Emre; Ayhan, Sevgi; Çağlar, Mete; Erkaya, Salım; Güngör, Tayfun

doi:10.7314/apjcp.2013.14.12.7635

Cited by 22 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…31 A recent study on the expression of SPAG9 has predicted presence of malignant endometrium with 74% sensitivity, 83% specificity, 88% PPV, and 64.5% NPV. 32 In our study, SPAG9 protein expression in IHC predicted presence of malignant SGT with 83.72% sensitivity, 100% specificity, 100% PPV, and 83.72% NPV. Further, in a recent study, SPAG9 overexpression was correlated with tumor stages in human hepatocellular carcinoma tissues (p < 0.001).…”

Section: Discussionsupporting

confidence: 47%

Sperm associated antigen 9(SPAG9) expression and humoral response in benign and malignant salivary gland tumors

et al. 2014

View full text Add to dashboard Cite

Keywords: biomarker, cancer testis antigen, early detection and diagnosis, immunotherapeutic target, SPAG9Salivary gland cancers are highly aggressive epithelial tumor associated with metastatic potential and high mortality. The tumors are biologically diverse and are of various histotypes. Besides, the detection and diagnosis is a major problem of salivary gland cancer for available treatment modalities. In the present study, we have investigated the association of sperm associated antigen 9 (SPAG9) expression with salivary gland tumor (SGT). Clinical specimens of benign (n D 16) and malignant tumors (n D 86) were examined for the SPAG9 expression. In addition, the sera and adjacent non-cancerous tissues (n D 72) from available patients were obtained. Our in situ RNA hybridization and immunohistochemistry (IHC) analysis revealed significant difference (p D 0.0001) in SPAG9 gene and protein expression in benign (63%) and malignant tumor (84%) specimens. Further, significant association was also observed between SPAG9 expression and malignant tumors (P D 0.05). A cut-off value of >10% cells expressing SPAG9 protein designated as positive in IHC, predicted presence of malignant SGT with 83.72% sensitivity, 100% specificity, 100% PPV and 83.72% NPV. Humoral response against SPAG9 protein was generated in 68% of SGT patients. A cut-off value of 0.212 OD for anti-SPAG9 antibodies in ELISA predicted presence of malignant SGT with 69.23% sensitivity, 100% specificity, 100% PPV and 78.94% NPV. Collectively, our data suggests that the majority of SGT show significant difference and association among benign and malignant tumors for SPAG9 gene and protein expression and also exhibit humoral response against SPAG9 protein. Hence, SPAG9 may be developed as a biomarker for detection and diagnosis of salivary gland tumors.

show abstract

Section: Discussionsupporting

confidence: 47%

Sperm associated antigen 9(SPAG9) expression and humoral response in benign and malignant salivary gland tumors

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Хавдрын молекул биологийн сүүлийн үеийн зарим судалгаанууд [25][26][27][28] хөхний, бүдүүн гэдэсний, элэгний гэх мэт олон төрлийн хавдрын үед JSAP2 уургийн экспресс нэмэгддэг болохыг тогтоосон нь ихээхэн сонирхол татаж байгаа юм. Одоогоор хорт хавдрын эсэд JSAP уургуудын гүйцэтгэх үүрэг, тэдгээрийн молекул механизм бүрэн тодорхой болоогүй байгаа хэдий ч олон судлаачид JSAP2 уургийг хавдрын оношлогоонд биомаркер болгон хэрэглэхийг санал болгох болов [25][26][27][28].…”

Section: оршилunclassified

“…Одоогоор хорт хавдрын эсэд JSAP уургуудын гүйцэтгэх үүрэг, тэдгээрийн молекул механизм бүрэн тодорхой болоогүй байгаа хэдий ч олон судлаачид JSAP2 уургийг хавдрын оношлогоонд биомаркер болгон хэрэглэхийг санал болгох болов [25][26][27][28].…”

Section: оршилunclassified

Хавдар Эсийн Үйл Ажиллагаанд Jsap (Jnk/Stress-Activated Protein Kinase-Associated Protein) Уургийн Оролцоо

Erdenebaatar¹,

Риота²,

Кацүжи³

2016

Proc. Mong. Acad. Sci.

View full text Add to dashboard Cite

show abstract

“…We demonstrated that SPAG9 was detected in approximately 72% of patients with EC but not in healthy controls, and its expression level was correlated to the degree of differentiation and to lymphatic metastasis [22]. Baser et al [23] detected that a cut-off value of 17 ng/ml for serum SPAG9 level predicted early-stage EC in asymptomatic high-risk women with 74% sensitivity and 83% specificity. Research also demonstrated that SPAG9 was engaged in the c-Jun N-terminal kinase (JNK) pathway [24], which was activated by the presence or absence of estrogen and progesterone [25].…”

Section: Introductionmentioning

confidence: 99%

<b><i>SPAG9</i></b> May Be a Potential Prognostic Marker of Endometrial Hyperplasia and Grade 1 Endometrioid Adenocarcinoma Treated with Progestin

Li¹,

Bai²,

Yan³

et al. 2015

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background: Sperm-associated antigen 9 (SPAG9), a recently characterized oncogene, may serve as a marker for the early diagnosis of endometrial cancer. However, whether SPAG9 can be a prognostic marker of complex atypical endometrial hyperplasia (CAEH) or grade 1 endometrioid adenocarcinoma (EA) treated with progestin is still unknown. Methods: Progestin therapy was performed in 27 women diagnosed with CAEH (19/27, CAEH group) or grade 1 EA (8/27, EA group). The expression of SPAG9 was measured in pre and post progestin-treated endometrial specimens by immunohistochemistry. The expression of SPAG9 was also examined by real-time polymerase chain reaction (PCR) and Western blot in Ishikawa cells and ECC-1 cells with or without progestin treatment. Results: (1) CAEH showed a significantly better therapeutic efficacy than EA. (2) The expression of SPAG9 was lower in CAEH than in EA. (3) SPAG9 expression significantly declined in the endometrial tissues of women responding to progestin. (4) Significant downregulations of SPAG9 were validated by reverse transcription PCR (RT-PCR) and Western blot both in Ishikawa cells and ECC-1 cells treated with progestin. Conclusion: SPAG9 may be associated with the efficacy of progestin treatment in CAEH and grade 1 EA. It may help to distinguish CAEH from grade 1 EA and serve as a new prognostic marker of CAEH or grade 1 EA treated with progestin.

show abstract

Sperm-Associated Antigen 9 is a Promising marker for Early Diagnosis of Endometrial Cancer

Cited by 22 publications

References 17 publications

Sperm associated antigen 9(SPAG9) expression and humoral response in benign and malignant salivary gland tumors

Sperm associated antigen 9(SPAG9) expression and humoral response in benign and malignant salivary gland tumors

Хавдар Эсийн Үйл Ажиллагаанд Jsap (Jnk/Stress-Activated Protein Kinase-Associated Protein) Уургийн Оролцоо

<b><i>SPAG9</i></b> May Be a Potential Prognostic Marker of Endometrial Hyperplasia and Grade 1 Endometrioid Adenocarcinoma Treated with Progestin

Contact Info

Product

Resources

About